Compare Biogen Inc (BIIB) vs Nebius Group NV (NBIS) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

NBIS stock trades at $249.82, up 35.69% in 24 hours, driven by strong Q2 2026 earnings beats and positive AI cloud demand sentiment. Technicals are bearish with key support at $190 and resistance at $196, while fundamentals show rapid revenue growth but negative EPS and high valuation multiples. Recent news highlights Michael Burry's short position alongside upbeat analyst coverage.

Outlook is mixed: high growth in AI infrastructure offers upside, but execution risks, negative earnings, and stretched valuations pose significant challenges. Analyst consensus is bullish with an $248.73 price target, yet competitive pressures and capital intensity require careful monitoring for sustained shareholder value.